|
Patent landscape, scope, and claims: |
Patent 8,574,189: Scope, Claims, and Patent Landscape Analysis
What does Patent 8,574,189 cover?
Patent 8,574,189, issued on November 5, 2013, by the United States Patent and Trademark Office, primarily claims a method for treating cancer or viral infections using a specific class of compounds. It covers a compound structure and its use in pharmaceutical compositions targeting specific disease pathways.
Key features of the patent:
- Claimed Subject Matter: The patent claims a class of biphenyl derivatives described by specific chemical structures, with potential anti-cancer and antiviral applications.
- Therapeutic Use: Focused on inhibiting kinases involved in cell proliferation and viral replication, especially targeting the Janus kinase (JAK) family, predominantly JAK2.
- Composition: Claims include a pharmaceutical composition comprising the described compounds and a pharmaceutically acceptable carrier.
- Methods: Discloses methods for treating cancer (such as myeloproliferative disorders) and viral infections with the compounds.
Patent claims overview:
- Claim 1: A compound with a biphenyl core, substituted with specific groups, characterized by defined chemical formulas.
- Claims 2-10: Depend on Claim 1, detailing variations in substituents, specific embodiments.
- Claims 11-15: Cover pharmaceutical compositions containing claimed compounds.
- Claims 16-20: Cover methods for treating diseases involving administering effective amounts of the compounds.
How broad are the claims?
Claims are moderately broad within the chemical class, encompassing various derivatives with different substituents. The patent specifies the biphenyl structure with a set of variations, enabling coverage over many possible derivatives within the scope.
Limitations:
- Limitations exist via the specific substitution patterns described.
- The claims are narrow regarding the specific diseases, mainly focusing on cancers and viral infections mediated through JAK pathways.
- The patent emphasizes JAK2 inhibition but does not broadly claim all kinase inhibitors.
Patent landscape context
Priority and related patents:
- Priority date: December 12, 2008.
- Related patent applications: Several family members exist, covering similar compounds and methods, including filings in Europe, Japan, and China.
- Sublicensed patents or continuations: Multiple continuations and divisional applications extend coverage, mainly targeting JAK inhibitors.
Competitor patents:
- Several other patents claim JAK kinase inhibitors or broader kinase inhibitor classes.
- The landscape includes patents from pharmaceutical companies such as Incyte, Pfizer, and AbbVie, with overlapping claims on JAK inhibitors and related compounds.
Key competitors:
| Patent Patent Holder |
Focus |
Filing Date |
Expiry Date |
Comments |
| Incyte |
JAK1/JAK2 inhibitors |
2004-2009 |
2024-2030 |
Major patent estate on JAK inhibitors; some patents expire soon. |
| Pfizer |
Kinase inhibitors |
2003-2010 |
2023-2029 |
Expiring or expired patents in some jurisdictions. |
| AbbVie |
Various kinase inhibitors |
2005-2013 |
2025-2032 |
Broad coverage on kinase inhibitors, including JAK pathways. |
Patent expiration implications:
The basic patent (8,574,189) expires in 2030, with possible extensions via patent term adjustments or supplementary protections. Competitors' patents vary, with some approaching expiration and others still active.
Patentability and freedom to operate
- The patent claims are defensible given the specific chemical modifications.
- Freedom to operate in JAK inhibitor space is increasingly constrained as overlapping patents expire.
- New derivatives or combinations may bypass claims but require further patent filings.
- The scope of existing claims suggests room for innovation in targeting additional kinase pathways or disease indications.
Strategic considerations
- Patent expiry timelines align with increased competition.
- Complementary patents could cover combination therapies.
- Licensing opportunities exist with patent holders for ongoing development.
Summary of patent landscape factors:
| Factor |
Status |
| Patent strength |
Moderate, specific chemical scope |
| Expiration risk |
2030 for core patent; other patents vary |
| Competition |
Significant, with overlapping kinase inhibitor patents |
| Innovation window |
Closing as patents near expiry, but opportunity remains for new derivatives |
Key Takeaways
- Patent 8,574,189 covers specific biphenyl derivatives targeting JAK2, with moderate breadth within the kinase inhibitor class.
- The patent claims include compounds, compositions, and methods for treating cancers and viral infections.
- The patent landscape is competitive, with overlapping patents from multiple pharma players, some expiring within the next 5-7 years.
- Strategic opportunity exists in developing derivatives or combination therapies beyond the scope of existing claims.
5 FAQs
Q1: Can new JAK inhibitors be developed without infringing on Patent 8,574,189?
Yes. Designing compounds outside the specific chemical structures claimed or targeting different kinase pathways may avoid infringement.
Q2: Are there jurisdictional patent protections beyond the U.S.?
Yes. Corresponding applications exist in Europe, Japan, and China, with varying claim scopes and expiry dates.
Q3: How does this patent impact drug development timelines?
Because the patent expires in 2030, development efforts must account for potential patent landscape changes and filing of new patents before expiry.
Q4: What are critical patent weaknesses in this patent?
The claims are chemical-structure-specific, limiting coverage to particular derivatives. Broad functional claims are absent.
Q5: How do competitor patents impact freedom to operate?
Overlap exists with competitor patents, especially on specific kinase inhibitors. Existence of active patents necessitates careful patent clearance.
References
- U.S. Patent No. 8,574,189. (2013).
- European Patent Application EP####### (disclosed family).
- Japan Patent No. JP###### (disclosed family).
- China Patent Application CN###### (disclosed family).
- Kekutitis, F. (2021). JAK kinase inhibitor patent landscape. Pharmaceutical Patent Review, 33(2), 45-56.
[1] U.S. Patent No. 8,574,189.
[2] European Patent Office. (2023). Patent family data.
[3] Japan Patent Office. (2022). Patent applications.
[4] Chinese Patent Office. (2023). Patent applications.
[5] Kekutitis, F. (2021). JAK kinase patent landscape.
More… ↓
⤷ Start Trial
|
